Skip to main content
BOLD logo

Boundless Bio, Inc.

BOLDNASDAQHealthcareBiotechnology

$2.36Today:- (-)1Y +73.05%

As of Oct 23, 2026 close

Market cap
$52.98M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.96$3.16
Volume (live)
-
Avg. volume (3M)
175.46K

Boundless Bio (BOLD) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Boundless Bio used $46.66M of cash in operating activities and spent $546.00K on capital expenditures. That left free cash flow of −$47.21M.

Boundless Bio Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Boundless Bio, Inc. (BOLD) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2018Dec 2017
Operating Activities
Net Income-58.20-65.36-49.43-45.90-25.21-128.82-90.24
Depreciation & Amortization1.251.090.960.940.687.463.75
Deferred Income Tax0.000.000.000.000.000.002.25
Stock Based Compensation6.137.523.342.291.160.006.88
Change in Working Capital3.46-1.68-0.800.87-0.84276.6223.42
Change in Accounts Payable1.630.781.661.911.224.080.69
Change in Other Working Capital3.29-0.302.39-1.05-1.60272.5422.74
Other Operating Activities3.29-4.552.392.210.50-279.73-30.57
Net Cash from Operating Activities-46.66-60.84-46.86-39.60-23.25-107.98-84.51
Investing Activities
Capital Expenditures-0.55-2.54-0.63-1.07-2.03-11.61-7.55
Purchases of Investments-174.90-208.47-160.12-42.60-77.49-382.03-152.71
Sales/Maturities of Investments213.24184.90122.5059.8020.24208.59126.83
Net Cash from Investing Activities37.80-26.10-38.2616.13-59.29-185.05-33.44
Financing Activities
Common Stock Issued0.1493.170.180.130.2114.6039.10
Common Stock Repurchased0.000.000.000.000.00-144.35-38.97
Other Financing Activities0.00-3.35-1.960.00105.53398.46120.55
Net Cash from Financing Activities0.1489.8297.900.13105.53398.46120.55
Summary
Net Change in Cash-8.722.8812.78-23.3422.99105.442.61
Cash at Beginning of Period27.1524.2711.4834.2911.8338.9136.36
Cash at End of Period18.4327.1524.2710.9534.82144.3538.97
Free Cash Flow-47.21-63.38-47.49-40.66-25.28-119.59-92.06

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Boundless Bio Cash Flow

What is Boundless Bio's free cash flow?

Boundless Bio had negative free cash flow of $47.21M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$46.66M minus $546.00K of capital expenditures.

How much does Boundless Bio spend on capital expenditures?

Boundless Bio spent $546.00K on capital expenditures in fiscal 2025, compared with $2.54M a year earlier.

Does Boundless Bio pay dividends or buy back shares?

Boundless Bio's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition